We are currently witnessing a “Neuroplasticity Revolution” that is redefining the landscape of mental health care. Traditional treatments have often focused on managing the symptoms of PTSD through daily medication, but the focus is now shifting toward remodeling the brain’s actual architecture. This approach aims to fix the “hardware” of the brain, rather than just […]
Archive for the ‘Pharma and Medical Device’ Category
The Future of PTSD Treatment: Beyond the Daily Pill
Posted by Michael A. S. Guth on April 5th, 2026
Posted in Neuroplasticity, Pharma and Medical Device 
Comments Off on The Future of PTSD Treatment: Beyond the Daily PillIn the 1950s, my physicist father met with Albert Einstein at the Institute for Advanced Study to discuss unified field theory.
Posted by Michael A. S. Guth on April 5th, 2026
In the 1950s, my physicist father, Eugene Guth, met with Albert Einstein at the Institute for Advanced Study to discuss unified field theory. Einstein, it turned out, was more interested in the philosophy of physics than the math, a topic equally of interest to my dad. See https://michaelguth.com/family/HistoryofPhysicsbyEugeneGuth.htm Mathematics and philosophy of physics have relevance […]
Posted in About, Featured, Neuroplasticity, Pharma and Medical Device Comments Off on In the 1950s, my physicist father met with Albert Einstein at the Institute for Advanced Study to discuss unified field theory.The FDA approval of Kresladi (marnetegragene autotemcel) on March 26, 2026
Posted by Michael A. S. Guth on April 2nd, 2026
The FDA approval of Kresladi (marnetegragene autotemcel) on March 26, 2026, is indeed a watershed moment for Rocket Pharmaceuticals and the LAD-I community. However, your question regarding the cost per patient touches on the most complex challenge in modern medicine: the “one-and-done” curative price tag. While Rocket Pharmaceuticals has not yet publicly released the official […]
Posted in Pharma and Medical Device Comments Off on The FDA approval of Kresladi (marnetegragene autotemcel) on March 26, 2026A New Blueprint for Turning an Orphan Brain Receptor into a Blockbuster Drug Target
Posted by Michael A. S. Guth on March 30th, 2026
Forthcoming in Drug Discovery Today: A New Blueprint for Turning an Orphan Brain Receptor into a Blockbuster Drug Target I am pleased to announce that my article, “Accelerating the Orphan GPCR Pipeline: GPR149 as a Case Study in Dual-Domain Target Validation,” has been accepted for publication in Drug Discovery Today, a leading journal for pharmaceutical strategy and […]
Posted in Neuroplasticity, Pharma and Medical Device Comments Off on A New Blueprint for Turning an Orphan Brain Receptor into a Blockbuster Drug Target“Chemo Brain” and Diabetes Research
Posted by Michael A. S. Guth on February 10th, 2026
Is the Next Breakthrough in “Chemo Brain” Treatment Hiding in Diabetes Research? For cancer survivors, the battle often doesn’t end with remission. Chemotherapy-Induced Cognitive Impairment (CICI)—widely known as “Chemo Brain”—remains one of the most debilitating long-term side effects of treatment, affecting memory, executive function, and attention. While the clinical impact is well-documented, therapeutic options remain […]
Posted in Featured, Neuroplasticity, Pharma and Medical Device Comments Off on “Chemo Brain” and Diabetes Research𝐖𝐡𝐲 𝐃𝐍𝐀 𝐎𝐫𝐢𝐠𝐚𝐦𝐢 𝐢𝐬 𝐭𝐡𝐞 𝐒𝐞𝐜𝐫𝐞𝐭 𝐭𝐨 𝐚 “𝐒𝐢𝐥𝐞𝐧𝐭” 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐒𝐜𝐚𝐟𝐟𝐨𝐥𝐝 𝐈𝐧 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐝𝐞𝐬𝐢𝐠𝐧,
Posted by Michael A. S. Guth on February 7th, 2026
𝐖𝐡𝐲 𝐃𝐍𝐀 𝐎𝐫𝐢𝐠𝐚𝐦𝐢 𝐢𝐬 𝐭𝐡𝐞 𝐒𝐞𝐜𝐫𝐞𝐭 𝐭𝐨 𝐚 “𝐒𝐢𝐥𝐞𝐧𝐭” 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐒𝐜𝐚𝐟𝐟𝐨𝐥𝐝 𝐈𝐧 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐝𝐞𝐬𝐢𝐠𝐧, “𝐨𝐟𝐟-𝐭𝐚𝐫𝐠𝐞𝐭” 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐞𝐬 𝐚𝐫𝐞 𝐚 𝐩𝐞𝐫𝐬𝐢𝐬𝐭𝐞𝐧𝐭 𝐡𝐮𝐫𝐝𝐥𝐞. 𝐖𝐡𝐞𝐧 𝐰𝐞 𝐮𝐬𝐞 𝐩𝐫𝐨𝐭𝐞𝐢𝐧-𝐛𝐚𝐬𝐞𝐝 𝐩𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬 𝐭𝐨 𝐝𝐞𝐥𝐢𝐯𝐞𝐫 𝐚𝐧 𝐚𝐧𝐭𝐢𝐠𝐞𝐧, 𝐭𝐡𝐞 𝐢𝐦𝐦𝐮𝐧𝐞 𝐬𝐲𝐬𝐭𝐞𝐦 𝐨𝐟𝐭𝐞𝐧 𝐠𝐞𝐭𝐬 𝐝𝐢𝐬𝐭𝐫𝐚𝐜𝐭𝐞𝐝 𝐚𝐧𝐝 𝐚𝐭𝐭𝐚𝐜𝐤𝐬 𝐭𝐡𝐞 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐯𝐞𝐡𝐢𝐜𝐥𝐞 𝐢𝐭𝐬𝐞𝐥𝐟 𝐢𝐧𝐬𝐭𝐞𝐚𝐝 𝐨𝐟 𝐭𝐡𝐞 𝐯𝐢𝐫𝐮𝐬. 𝐍𝐞𝐰 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐟𝐫𝐨𝐦 𝐌𝐈𝐓 𝐚𝐧𝐝 𝐒𝐜𝐫𝐢𝐩𝐩𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐢𝐧 𝐒𝐜𝐢𝐞𝐧𝐜𝐞, […]
Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on 𝐖𝐡𝐲 𝐃𝐍𝐀 𝐎𝐫𝐢𝐠𝐚𝐦𝐢 𝐢𝐬 𝐭𝐡𝐞 𝐒𝐞𝐜𝐫𝐞𝐭 𝐭𝐨 𝐚 “𝐒𝐢𝐥𝐞𝐧𝐭” 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐒𝐜𝐚𝐟𝐟𝐨𝐥𝐝 𝐈𝐧 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐝𝐞𝐬𝐢𝐠𝐧,𝗡𝗜𝗖𝗘 𝗥𝗲𝗰𝗼𝗺𝗺𝗲𝗻𝗱𝘀 𝗗𝘂𝗽𝗶𝗹𝘂𝗺𝗮𝗯 𝗳𝗼𝗿 𝗘𝗼𝘀𝗶𝗻𝗼𝗽𝗵𝗶𝗹𝗶𝗰 𝗖𝗢𝗣𝗗: 𝗔 𝗗𝗲𝗲𝗽 𝗗𝗶𝘃𝗲 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗖𝗮𝘀𝗲
Posted by Michael A. S. Guth on February 7th, 2026
𝗡𝗜𝗖𝗘 𝗥𝗲𝗰𝗼𝗺𝗺𝗲𝗻𝗱𝘀 𝗗𝘂𝗽𝗶𝗹𝘂𝗺𝗮𝗯 𝗳𝗼𝗿 𝗘𝗼𝘀𝗶𝗻𝗼𝗽𝗵𝗶𝗹𝗶𝗰 𝗖𝗢𝗣𝗗: 𝗔 𝗗𝗲𝗲𝗽 𝗗𝗶𝘃𝗲 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗖𝗮𝘀𝗲 𝗧𝗵𝗲 𝗨𝗞’𝘀 𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗲 𝗳𝗼𝗿 𝗛𝗲𝗮𝗹𝘁𝗵 𝗮𝗻𝗱 𝗖𝗮𝗿𝗲 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 (𝗡𝗜𝗖𝗘) 𝗵𝗮𝘀 𝗶𝘀𝘀𝘂𝗲𝗱 𝗳𝗶𝗻𝗮𝗹 𝗱𝗿𝗮𝗳𝘁 𝗴𝘂𝗶𝗱𝗮𝗻𝗰𝗲 𝗿𝗲𝗰𝗼𝗺𝗺𝗲𝗻𝗱𝗶𝗻𝗴 𝗱𝘂𝗽𝗶𝗹𝘂𝗺𝗮𝗯 𝗮𝘀 𝗮𝗻 𝗮𝗱𝗱-𝗼𝗻 𝗺𝗮𝗶𝗻𝘁𝗲𝗻𝗮𝗻𝗰𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗳𝗼𝗿 𝗮 𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰, 𝗵𝗶𝗴𝗵-𝗻𝗲𝗲𝗱 𝗖𝗢𝗣𝗗 𝗽𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻. 𝗧𝗵𝗶𝘀 𝗺𝗮𝗿𝗸𝘀 𝗮 𝗽𝗶𝘃𝗼𝘁𝗮𝗹 𝘀𝗵𝗶𝗳𝘁 𝘁𝗼𝘄𝗮𝗿𝗱𝘀 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗶𝗻 𝗰𝗵𝗿𝗼𝗻𝗶𝗰 𝗿𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗱𝗶𝘀𝗲𝗮𝘀𝗲. […]
Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on 𝗡𝗜𝗖𝗘 𝗥𝗲𝗰𝗼𝗺𝗺𝗲𝗻𝗱𝘀 𝗗𝘂𝗽𝗶𝗹𝘂𝗺𝗮𝗯 𝗳𝗼𝗿 𝗘𝗼𝘀𝗶𝗻𝗼𝗽𝗵𝗶𝗹𝗶𝗰 𝗖𝗢𝗣𝗗: 𝗔 𝗗𝗲𝗲𝗽 𝗗𝗶𝘃𝗲 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗖𝗮𝘀𝗲The 2026 Transatlantic Market Access Pivot: An Architectural Framework
Posted by Michael A. S. Guth on January 22nd, 2026
Market Access 2026: Transatlantic Pivot Toolkit A Strategic Resource for Founders & VCs Navigating the EU JSC & NHS Threshold Shifts Prepared by Michael A. S. Guth, Ph.D., J.D. | Strategic Systems Architect for High-Complexity Biologics, Drugs, and Device combinations Executive Summary The 2026 regulatory-access landscape has fundamentally shifted with two parallel developments: EU’s Joint […]
Posted in AI Governance, Pharma and Medical Device, Regulatory Medical Writing Comments Off on The 2026 Transatlantic Market Access Pivot: An Architectural Framework𝐁𝐞𝐲𝐨𝐧𝐝 𝐂𝐎𝐕𝐈𝐃-𝟏𝟗: 𝐓𝐡𝐞 𝐍𝐞𝐱𝐭 𝐅𝐫𝐨𝐧𝐭𝐢𝐞𝐫𝐬 𝐟𝐨𝐫 𝐦𝐑𝐍𝐀 𝐚𝐧𝐝 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦𝐬 𝐢𝐧 𝐆𝐥𝐨𝐛𝐚𝐥 𝐈𝐦𝐦𝐮𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧
Posted by Michael A. S. Guth on January 15th, 2026
𝐓𝐡𝐞 𝐫𝐚𝐩𝐢𝐝 𝐦𝐚𝐭𝐮𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐦𝐑𝐍𝐀-𝐋𝐍𝐏 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐢𝐬 𝐜𝐚𝐭𝐚𝐥𝐲𝐳𝐢𝐧𝐠 𝐚 𝐧𝐞𝐰 𝐞𝐫𝐚 𝐢𝐧 𝐯𝐚𝐜𝐜𝐢𝐧𝐨𝐥𝐨𝐠𝐲, 𝐦𝐨𝐯𝐢𝐧𝐠 𝐝𝐞𝐜𝐢𝐬𝐢𝐯𝐞𝐥𝐲 𝐛𝐞𝐲𝐨𝐧𝐝 𝐩𝐚𝐧𝐝𝐞𝐦𝐢𝐜 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐞. 𝐓𝐡𝐞 𝟐𝟎𝟐𝟔 𝐨𝐮𝐭𝐥𝐨𝐨𝐤 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐬𝐞𝐯𝐞𝐫𝐚𝐥 𝐜𝐨𝐧𝐯𝐞𝐫𝐠𝐞𝐧𝐭 𝐭𝐫𝐚𝐜𝐤𝐬: 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧: 𝐓𝐡𝐞 𝐜𝐨𝐫𝐞 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧—𝐮𝐬𝐢𝐧𝐠 𝐋𝐍𝐏𝐬 𝐭𝐨 𝐝𝐞𝐥𝐢𝐯𝐞𝐫 𝐑𝐍𝐀 𝐬𝐞𝐪𝐮𝐞𝐧𝐜𝐞𝐬 𝐞𝐧𝐜𝐨𝐝𝐢𝐧𝐠 𝐩𝐫𝐨𝐭𝐞𝐢𝐧 𝐢𝐦𝐦𝐮𝐧𝐨𝐠𝐞𝐧𝐬—𝐢𝐬 𝐛𝐞𝐢𝐧𝐠 𝐝𝐞𝐩𝐥𝐨𝐲𝐞𝐝 𝐚𝐠𝐚𝐢𝐧𝐬𝐭 𝐡𝐢𝐬𝐭𝐨𝐫𝐢𝐜𝐚𝐥𝐥𝐲 𝐢𝐧𝐭𝐫𝐚𝐜𝐭𝐚𝐛𝐥𝐞 𝐩𝐚𝐭𝐡𝐨𝐠𝐞𝐧𝐬. 𝐅𝐨𝐫 𝐇𝐈𝐕, 𝐠𝐞𝐫𝐦𝐥𝐢𝐧𝐞-𝐭𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐰𝐢𝐭𝐡 𝐬𝐞𝐪𝐮𝐞𝐧𝐭𝐢𝐚𝐥 𝐦𝐑𝐍𝐀 𝐛𝐨𝐨𝐬𝐭𝐞𝐫𝐬 𝐚𝐢𝐦 𝐭𝐨 𝐠𝐮𝐢𝐝𝐞 […]
Posted in Pharma and Medical Device Comments Off on 𝐁𝐞𝐲𝐨𝐧𝐝 𝐂𝐎𝐕𝐈𝐃-𝟏𝟗: 𝐓𝐡𝐞 𝐍𝐞𝐱𝐭 𝐅𝐫𝐨𝐧𝐭𝐢𝐞𝐫𝐬 𝐟𝐨𝐫 𝐦𝐑𝐍𝐀 𝐚𝐧𝐝 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦𝐬 𝐢𝐧 𝐆𝐥𝐨𝐛𝐚𝐥 𝐈𝐦𝐦𝐮𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧𝗔𝗥𝗘 𝗪𝗘 𝗡𝗢𝗪 𝗜𝗡 𝗧𝗛𝗘 𝗕𝗨𝗦𝗜𝗡𝗘𝗦𝗦 𝗢𝗙 𝗥𝗘𝗜𝗠𝗕𝗨𝗥𝗦𝗜𝗡𝗚 “𝗡𝗢𝗡-𝗜𝗡𝗙𝗘𝗥𝗜𝗢𝗥?”
Posted by Michael A. S. Guth on January 8th, 2026
𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲 𝘁𝗵𝗲 𝗽𝗿𝗲𝗺𝗶𝘀𝗲 𝗼𝗳 𝗰𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗶𝗻𝗴 𝗻𝗼𝗻-𝗶𝗻𝗳𝗲𝗿𝗶𝗼𝗿𝗶𝘁𝘆 𝗶𝗻 𝗮 𝗺𝗮𝘁𝘂𝗿𝗲 𝗺𝗮𝗿𝗸𝗲𝘁 𝗮𝗻𝗱 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻 𝘁𝗵𝗲 𝗵𝗲𝗮𝗹𝘁𝗵 𝗲𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹𝗲. 𝗛𝗲𝗮𝗱𝗹𝗶𝗻𝗲: 𝗔 𝗡𝗲𝘄 𝗣𝗶𝗹𝗹 𝗳𝗼𝗿 𝗛𝗜𝗩: 𝗜𝗻𝗰𝗿𝗲𝗺𝗲𝗻𝘁𝗮𝗹 𝗖𝗵𝗮𝗻𝗴𝗲 𝗼𝗿 𝗣𝗿𝗶𝗰𝗲𝗱 𝗮𝘀 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻? 𝗚𝗶𝗹𝗲𝗮𝗱’𝘀 𝗔𝗥𝗧𝗜𝗦𝗧𝗥𝗬-𝟮 𝘁𝗿𝗶𝗮𝗹 𝘀𝗵𝗼𝘄𝘀 𝗶𝘁𝘀 𝗻𝗲𝘄 𝗕𝗜𝗖/𝗟𝗘𝗡 𝘀𝗶𝗻𝗴𝗹𝗲-𝘁𝗮𝗯𝗹𝗲𝘁 𝗿𝗲𝗴𝗶𝗺𝗲𝗻 𝗶𝘀 𝗻𝗼𝗻-𝗶𝗻𝗳𝗲𝗿𝗶𝗼𝗿 𝘁𝗼 𝗶𝘁𝘀 𝗼𝘄𝗻 𝗯𝗹𝗼𝗰𝗸𝗯𝘂𝘀𝘁𝗲𝗿, 𝗕𝗜𝗞𝗧𝗔𝗥𝗩𝗬, 𝗳𝗼𝗿 𝘃𝗶𝗿𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹𝗹𝘆 𝘀𝘂𝗽𝗽𝗿𝗲𝘀𝘀𝗲𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀. 𝗧𝗵𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗶𝘀 𝘀𝗼𝘂𝗻𝗱, 𝗯𝘂𝘁 𝗶𝘁 𝗽𝗿𝗼𝗺𝗽𝘁𝘀 […]
Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on 𝗔𝗥𝗘 𝗪𝗘 𝗡𝗢𝗪 𝗜𝗡 𝗧𝗛𝗘 𝗕𝗨𝗦𝗜𝗡𝗘𝗦𝗦 𝗢𝗙 𝗥𝗘𝗜𝗠𝗕𝗨𝗥𝗦𝗜𝗡𝗚 “𝗡𝗢𝗡-𝗜𝗡𝗙𝗘𝗥𝗜𝗢𝗥?”